Follow the reading at Luxury Peptides
These are the sources used in the guide. The notes explain what each can tell us and where its answer stops. There's no need to read them all: start with the question that brought you here, then follow the relevant link.
Skin findings, up close
Collagen production in human skin cells — Maquart and colleagues, FEBS Letters, 1988. Cells grown in dishes made more collagen after exposure to GHK-Cu, without an increase in cell number. This helps explain the interest in the ingredient. It didn't measure firmer skin in people.
A review of GHK in skin research — Pickart, Vasquez-Soltero and Margolina, BioMed Research International, 2015. This review describes the often-cited cream findings from studies of women around 50. Some original accounts were conference or book material. We're reading the review's summary, with less trial detail available to check.
Topical GHK and the skin barrier — Mortazavi, Mohammadi Vadoud and Moghimi, BioImpacts, 2025. A review of wrinkle research, how the ingredient holds up and how it gets through skin. It highlights limited clinical studies. A reason to investigate an ingredient is different from knowing how reliably a finished cream works.
Copper-peptide skincare after laser treatment — Miller and colleagues, Archives of Facial Plastic Surgery, 2006. Satisfaction was higher, but objective wrinkle and overall skin-quality assessments found no significant improvement. This was a small study on laser-treated skin, which limits how broadly we can read it.
The ingredients behind GLOW
A review of peptide therapies — Mendias and Awan, Sports Medicine, 2026. This discusses individual peptides and their uneven evidence. Mentioning GLOW's ingredients doesn't make it a controlled human test of the mixture. The blend's benefits and safety remain separate questions.
Human reports involving BPC-157 — McGuire and colleagues, Current Reviews in Musculoskeletal Medicine, 2025. This review describes small, preliminary human reports and a lack of large, rigorous trials. Those reports concern BPC-157, not the complete GLOW blend.
Safety and approval
FDA's compounding safety concerns — Page current as of April 22, 2026. Injectable GHK-Cu, BPC-157 and TB-500 appear among withdrawn nominations. That isn't approval or clearance for compounding. The FDA's safety concerns remain beside the entries.
FDA's TB-500 review — Advisory-committee material, 2026. FDA found no published study giving TB-500 to people. The document also distinguishes this fragment from full-length thymosin beta-4. It's evidence about that distinction, not a record of an approval decision.
Compounding questions and answers — FDA. Compounded medicines aren't FDA-approved. These medicines reach the market without an FDA check of their quality, safety or effectiveness. A prescription and FDA approval answer different questions; one doesn't stand in for the other.